🎧 The Too-Good-To-Be-True Cancer Cure | On the Media | WNYC Studios

Listened to The Too-Good-To-Be-True Cancer Cure from On the Media | WNYC Studios

If possible, click to play, otherwise your browser may be unable to play this audio file.

Despite steadily declining rates of cancer deaths over the past two decades, cancer remains responsible for 1 in every 6 deaths worldwide. It’s a scourge. So when, this week, an Israeli company called Accelerated Evolution Biotechnologies captured the news cycle with promises of a complete cure for cancer within the year, the story caught fire.

The company’s technology is called “MuTaTo” — that's multi-target toxin. And, to judge from the news media this week, it seems vetted, verified and veering us all toward a cancer-free future. Reports began in the Jerusalem Post, but quickly took off, making their way into various Murdoch-owned publications like FOX and the New York Post and landing in local news outlets around the country and the globe.

A couple days into the fanfare, the skeptics started coming out: for one thing, as oncologist David Gorski points out in his blog “Respectful Insolence,” the claims are based on experiments with mice: no human trials have yet started. For another, they haven’t been sufficiently peer reviewed. In fact, the company won’t share its research, claiming it can’t afford the expense. The too-good-to-be-true story appears to be just that, built on PR puffery. But who can resist a good cancer cure?

With Mutato in mind, for this week’s podcast extra, we revisit our Breaking News Consumer’s Handbook: Health News edition, with Gary Schwitzer, publisher & founder of HealthNewsReview.org.

This is a fantastic piece of reporting relating to improved journalism and media consumption with respect to the frequent health studies seen in the main stream media. For those interested, here’s a link to the original version from 2015.